NCT06083857 2026-03-11
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
Clinical Trials
3 trialsNCT03940703 2026-02-27
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
EMD Serono
Phase 2 Active not recruiting
NCT06106802 2026-02-23
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Samsung Medical Center
Phase 2 Recruiting